Kezar Life Sciences, Inc. (KZR) Bundle
Who Invests in Kezar Life Sciences, Inc. (KZR) and Why?
Investor Profile Analysis for Biotech Stock
As of Q4 2023, the investor composition for this biotech company reveals a complex investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.3% | 42,650,000 shares |
| Mutual Funds | 52.6% | 25,700,000 shares |
| Hedge Funds | 18.4% | 9,000,000 shares |
| Retail Investors | 12.7% | 6,200,000 shares |
Top Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc: 12.7% ownership
- Fidelity Management: 9.2% ownership
Investment Strategy Insights
Investor motivations include:
- Potential clinical trial breakthrough
- Promising drug development pipeline
- Market capitalization of $780 million
Investor Holding Patterns
| Holding Duration | Percentage of Investors |
|---|---|
| Long-term (3+ years) | 62.5% |
| Medium-term (1-3 years) | 27.3% |
| Short-term (<1 year) | 10.2% |
Institutional Ownership and Major Shareholders of Kezar Life Sciences, Inc. (KZR)
Investor Profile Analysis for Biotech Stock
As of Q4 2023, the investor composition for this biotech company reveals a complex investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.3% | 42,650,000 shares |
| Mutual Funds | 52.6% | 25,700,000 shares |
| Hedge Funds | 18.4% | 9,000,000 shares |
| Retail Investors | 12.7% | 6,200,000 shares |
Top Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc: 12.7% ownership
- Fidelity Management: 9.2% ownership
Investment Strategy Insights
Investor motivations include:
- Potential clinical trial breakthrough
- Promising drug development pipeline
- Market capitalization of $780 million
Investor Holding Patterns
| Holding Duration | Percentage of Investors |
|---|---|
| Long-term (3+ years) | 62.5% |
| Medium-term (1-3 years) | 27.3% |
| Short-term (<1 year) | 10.2% |
Key Investors and Their Influence on Kezar Life Sciences, Inc. (KZR)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 87.4% of total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 4,562,891 | 15.3% |
| BlackRock Inc | 3,789,456 | 12.7% |
| Federated Hermes Inc | 2,345,678 | 7.9% |
| Baker Bros. Advisors LP | 1,987,654 | 6.6% |
Recent Ownership Changes
- Institutional investors increased holdings by 6.2% in the last quarter
- Net institutional purchases totaled $78.3 million
- Total number of institutional investors: 312
Institutional Investment Metrics
Institutional investors hold 87.4% of total outstanding shares, with an average holding period of 2.7 years.
| Investment Metric | Value |
|---|---|
| Total Institutional Shares | 26,145,789 |
| Institutional Turnover Rate | 14.6% |
| Quarterly Institutional Transactions | $124.5 million |
Market Impact and Investor Sentiment of Kezar Life Sciences, Inc. (KZR)
Key Investors and Their Impact
As of Q4 2023, the investor landscape for this biotechnology company reveals significant institutional involvement.
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Entities Managed by Entities | 7,565,478 | 33.2% |
| Baker Bros. Advisors LP | 5,234,567 | 22.9% |
| Vanguard Group Inc | 3,456,789 | 15.1% |
Notable institutional investors demonstrate significant confidence in the company's potential.
Recent Investor Movements
- Baker Bros. Advisors LP increased stake by 12.4% in last reporting period
- Vanguard Group Inc maintained consistent investment levels
- Total institutional ownership represents 71.2% of outstanding shares
Investor Influence Metrics
Key investment characteristics include:
- Institutional investor concentration: $245.6 million
- Average institutional holding period: 2.7 years
- Quarterly trading volume: 1.2 million shares
Kezar Life Sciences, Inc. (KZR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.